Citation Impact
Citing Papers
A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A
1994
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
2010
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Hydrogels in Regenerative Medicine
2009 Standout
Half-life of the maternal IgG1 allotype in infants
1993
Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease
2013
Botulinum Toxin as a Biological Weapon
2001 Standout
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
2018 Standout
Coronary risk factors in acute Kawasaki disease: Correlation of serum immunoglobulin levels with coronary complications
1998
Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations
2009
The Use of Intravenous Immune Globulin in Immunodeficiency Diseases
1991
The epidemiology of inhibitors in haemophilia A: a systematic review
2003
A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome
1991 Standout
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS
2022 StandoutNobel
The Use of Fibrin Glue in Skin Grafts and Tissue-Engineered Skin Replacements: A Review
2001
Graft-versus-host disease
2009 Standout
Blood protein predictors of brain amyloid for enrichment in clinical trials?
2015 StandoutNobel
Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering
2005 Standout
Variability in Delivery of Care and Echocardiogram Surveillance of Kawasaki Disease
2012
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy
2006
Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome
2002
Role of the gut microbiota in host appetite control: bacterial growth to animal feeding behaviour
2016
Stress-induced immune dysfunction: implications for health
2005 Standout
Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose
1997
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
2000 Standout
Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature
2006
Perceived Stress and Psychological Well-Being Are Associated With Antibody Status After Meningitis C Conjugate Vaccination
2002
Surgery and inhibitor development in hemophilia A: a systematic review
2011
22q11.2 deletion syndrome
2015 Standout
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Chronic Lymphocytic Leukemia
1995
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
1998 Standout
Intravenous immunoglobulin for the treatment of Kawasaki disease in children
2003
State of the Art in Burn Treatment
2005
Advances in skin grafting and treatment of cutaneous wounds
2014 StandoutScience
Intravenous immunoglobulin–related hemolysis in patients treated for Kawasaki disease
2015
Prevention and Treatment of Cancer-Related Infections
2012
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination
2016
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
2004 Standout
Pharmacokinetics of Coagulation Factors
2001
A Review of Keratinocyte Delivery to the Wound Bed
2004
Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease
2004
Long-term Consequences of Kawasaki Disease
1996 Standout
Salicylate for the treatment of Kawasaki disease in children
2006
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor
1995
Burn Wound Infections
2006 Standout
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
2001
Diagnosis and therapy of Kawasaki disease in children.
1993
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease
2004 Standout
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Guidelines for the management of hemophilia
2012 Standout
Works of M Lee being referenced
Use of Fibrin Sealant in Thermal Injury
1997
Treatment of Kawasaki syndrome: A comparison of two dosage regimens of intravenously administered immune globulin
1990
Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes
1994
A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
1997
A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A
1997
Predictors of infection in chronic lymphocytic leukaemia (CLL)
1992
The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.
1988
Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M)
1992